Comparative Pharmacology
Head-to-head clinical analysis: ASACOL versus MELAMISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL versus MELAMISA.
ASACOL vs MELAMISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asacol (mesalamine) is an aminosalicylate that exerts anti-inflammatory effects in the colon via inhibition of prostaglandin and leukotriene synthesis, particularly by blocking cyclooxygenase and lipoxygenase pathways, and by scavenging reactive oxygen species. It also inhibits cytokine production and reduces mucosal inflammation.
Meloxicam selectively inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandins involved in inflammation, pain, and fever, while sparing COX-1 activity at therapeutic doses.
800 mg orally three times daily or 1600 mg three times daily for 6 weeks; maintenance: 1.6 g daily in divided doses.
100 mg orally twice daily for 5 days; take with food.
None Documented
None Documented
Terminal half-life: 0.6-1.4 hours for 5-ASA; 6-12 hours for N-acetyl-5-ASA. Clinical context: short t1/2 necessitates multiple daily dosing for sustained colonic exposure.
Terminal elimination half-life is 6.5–9.8 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (80% as 5-ASA and N-acetyl-5-ASA), fecal (20%)
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (approximately 30%), with minor pulmonary elimination. Total clearance is about 1.2 mL/min/kg.
Category C
Category C
Aminosalicylate
Aminosalicylate